Boryung Pharmaceutical said Wednesday it will make an incremental 24 billion won ($20 million) investment in innovative US health care firms. The investment will be carried out over three years by Hayan I, L.P., which is a corporate venture capital fund established in the US by Boryung. Boryung Pharmaceutical plans to strengthen its pipelines for novel drugs development through open innovation with the promising companies it invests in in the US. Boryung’s US entity, Hayan Health Netwo

Samsung Display said Wednesday it anticipates to begin mass production of quantum-dot panels from 2021. The company held a celebratory event at its facility in Asan, South Chungcheong Province, where CEO Lee Dong-hoon oversaw the delivery of the first batch of QD manufacturing equipment. “Despite the COVID-19 pandemic, our close collaborative ecosystem with global partners enabled us to carry out our QD investments according to plan,” said Choi Joo-sun, chief of large-size display

Yuhan Corp. announced Wednesday it has licensed GI Innovation’s next-generation allergy treatment pipeline in a deal that could potentially total $1.2 billion. 　“I am very pleased by this collaboration with GI Innovation to develop the next-generation allergy treatment across all four major allergic diseases; allergic asthma, chronic urticaria, atopic dermatitis and food allergy, improving the lives of pediatric and adult patients who suffer from allergies” said Yuhan Preside

Huons Global said Tuesday that it will be the first South Korean firm to supply high-filtration masks to the state of Washington in the US. “This deal shows that Huons’ epidemic prevention products have gained trust. We are also exchanging messages with the state of New York, where we anticipate to sign more deals,” said Um Key-an, CEO of Huons. Huons had signed deals to export various epidemic prevention tools to the US since May. The six deals amount to roughly 8 billi

Global science and technology company Merck has opened the Korea Advanced Technology Center in Songtan Industrial Complex in Pyeongtaek, Gyeonggi Province, the company said Tuesday. “K-ATeC,” according to Merck, is a state-of-the-art facility that supports research and development for chemical mechanical polishing slurries as well as for the post-CMP cleaning of cutting-edge semiconductor devices.  “Korea is an important innovation and production hub for Merck. We ha

Hugel expects to begin distributing its wrinkle-smoothening botulinum toxin in the $1 billion European market in mid-2021, the company announced Tuesday. Hugel and its European distribution partner, Croma Pharma, have successfully completed phase 3 clinical trials in January 2019 and completed the submission of New Drug Application with the European Medicines Agency on Monday. As the standard review process takes roughly a year, Hugel expects to receive the approval in mid-2021. “Eur

We know this by many names. Poo, feces, stool, turd, excrement. ... The list can grow endless if imaginative children join in. But scatology is not a matter to be lightly regarded, as “gut feelings” take on a literal meaning in health care. Chunlab, a microbiome research firm, on Tuesday launched three-step services analyzing feces for personalized health care. Chunlab’s Gut Inside survey collects excrement in a bag and analyzes the beneficial and harmful bacteria found in i

Korean information technology firm NHN said Monday it has launched an automated in-hospital messenger service setting out to streamline medical professionals’ workflow. The system is optimal for cases where medical professionals from several disciplines have to collaborate, NHN said. TOAST MedicalTalk will first be applied at Severance Hospital in Yongin, Gyeonggi Province. The communication tool aids medical professionals in delivering patient-centered treatment. It combines the preexi

LabGenomics, a molecular diagnostics health care company, developed the world’s first 35-minute real-time polymerase chain reaction test kit for COVID-19. The company’s shares, listed on the tech-heavy Kosdaq, hit the daily growth ceiling of 30 percent on the day of the announcement Wednesday and continued to be upbeat in early morning trading Thursday, rising by 14.17 percent. Before, RT-PCR test kits for COVID-19 could yield results as fast as 2 1/2 hours. LabGenomics’ 35

Novel drugs developer Hanmi Science vowed Thursday to rev up its engine for Cydio Cigma -- six goals, standing for cyber education, digital bio, oral bio, city bio, green bio and marine Bio. “Where there is no innovation, there is no development. Those who turn their backs on challenges are branded as cowards. Cydio Cigma is our goal and commitment for the post-COVID-19 era,” said Hanmi Science CEO Lim Chong-yoon at a meeting with executives in June. Lim promised to reward employe

Investors were highly enthusiastic about the initial public offering of SK Biopharmaceuticals in the two-day retail tranche that wrapped up Wednesday, as it was oversubscribed 323 times with deposit payments amounting to 30.98 trillion won ($25.8 billion). The deposit payments -- 50 percent of the offering price -- reached 19.5 trillion won by noon and then zoomed up, according lead underwriter NH Investment & Securities. The drugmaker specializes in developing novel medicines for central

  진행: 임정요, Kevin Lee Selzer 1. Leafleting: decisive propaganda or empty provocation? 아이튠즈(아이폰): https://itunes.apple.com/kr/podcast/koliaheleoldeu-paskaeseuteu/id686406253?mt=2 팟빵 (안드로이드): http://www.podbbang.com/ch/6638 [1] Even in the 21st century with all its technical wizardry and social media, old-fashioned propaganda leaflets seem to matter a great deal on Korean Peninsula, the world’s last remaining Cold War frontier. *wizardry: 마법 *social media: SNS *old-fashioned: 고전적인

Samsung Biologics shares started upbeat Wednesday morning, up 2.62 percent from a day before, in light of its disclosure that it has nabbed a contract manufacturing deal worth $314 million with a European biopharmaceutical firm. The size of this new deal is as big as 54.3 percent the company’s revenue in 2019 at 701.6 billion won ($582 million). Combined with two other deals inked earlier in June, Samsung Biologics has already achieved 95.57 percent of last year’s revenue in the f

Celltrion shares rose 7.58 percent on Tuesday, following news that an Italian COVID-19 patient tested negative for the virus a week after being treated with Celltrion’s autoimmune disease treatment Remsima. Celltrion Healthcare, the global distributing arm of biologics drug manufacturer Celltrion, said that a patient in an Italian national hospital in Milan who had symptoms of pneumonia due to SARS CoV-2 infection, was treated with Remsima, and was discharged a week later after recovery.

Boryung Pharmaceutical presented the outcomes of the preclinical tests of its innovative blood cancer treatment on Tuesday at the American Association for Cancer Research, saying that the BR101801 pipeline showed more potency than existing phosphoinositide 3-kinase drugs in animal models. BR101801, a targeted cancer treatment and immuno-oncology drug that is being independently studied by Boryung Pharmaceutical, can simultaneously suppress the activities of PI3K and DNA-dependent protein kinase